AnaptysBio to Present at Wedbush PacGrow Healthcare Conference
August 08, 2017 06:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio to Participate in Upcoming Investor Conferences
June 01, 2017 06:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update
May 11, 2017 16:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Announces First-In-Human Dosing of ANB019
April 06, 2017 08:00 ET
|
AnaptysBio, Inc.
SAN DIEGO, April 06, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Announces 2016 Operating Results and Pipeline Progress
March 08, 2017 16:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting
March 04, 2017 15:00 ET
|
AnaptysBio, Inc.
SAN DIEGO, March 04, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings
February 13, 2017 08:00 ET
|
AnaptysBio, Inc.
SAN DIEGO, Feb. 13, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 31, 2017 17:00 ET
|
AnaptysBio, Inc.
SAN DIEGO, Jan. 31, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Announces Pricing of Initial Public Offering
January 25, 2017 19:00 ET
|
AnaptysBio, Inc.
SAN DIEGO, Jan. 25, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...